📰 BloombergBloombergQwen · 实盘可交易 · 多空市场:美股▼ 亏 -7.61% · 已结算 · 2 腿均把握 6/10
北京时间·🕒 发布 20:03:54决策时所见发布时间偏差 −8h(已更正)·⟳ 抓取 20:09:33 +5m39s·⚡ 决策 09-03 20:16:04 +6m31s·53.8 天前
Bloomberg盘前综述：Snowflake财报大超预期涨23%、Ultragenyx药物三期失败跌47%、Broadcom指引略低于预期
Snowflake财报大幅超预期+上调指引构成明确正向催化，多家券商目标价$425-$450远高于当前盘前价$376，仍有13-20%上行空间；Ultragenyx药物失败构成明确做空催化但-47%后剩余edge有限，给probe仓位
📄 原文Bloomberg↗ 原文
S&P 500 Index futures are little changed as of 7:53 a.m. in New York. Technology shares are in focus, following results…
▼ 亏 -6.88%入场 09-03 盘前首笔 @378.50 → 离场 09-04 常规开盘 @353.63
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(价格在入场线上方)、绿底 = 亏
💡 交易逻辑Q2大超预期+上调指引，目标$425-450仍高于盘前价13-20%，事件前无抢跑属真实surprise
怎么买 限价买入 不高于 378、仅下一个交易日，不成交作废
怎么卖 止盈 +8%(半仓)/+15%(清仓) · 止损 -6% · 时间止损 3日
▼ 亏 -8.33%入场 09-03 盘前首笔 @14.32 → 离场 09-04 常规开盘 @15.47
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(做空:价格在入场线下方)、绿底 = 亏
💡 交易逻辑Phase 3 Angelman药物确定性失败+多家降级，分析师目标下调和基金清仓卖压仍将持续1-2日
怎么做空 开盘做空 不低于 15.5（低于下限不成交）
怎么平空 止盈 -8%(半仓)/-15%(清仓) · 止损 +10% · 时间止损 2日
不做 Broadcom（AVGO.US）
Q4指引仅低于预期0.7%($34.8B vs $35.03B)，AI收入+221% YoY仍极强，不构成方向性交易；-3.6%反应属温和失望，无明确做空催化
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做多 SNOW.US Snowflake
建仓日早于近 30 天,只有日线图
做空 RARE.US Ultragenyx Pharmaceutical
建仓日早于近 30 天,只有日线图
成交明细 · 纸面
做多 SNOW.US Snowflake
| 收益状态 | -6.88% 已平仓 |
|---|---|
| 进场成交 | 2026-09-03 · 盘前首笔 · 09-03 16:01 北京 · @378.5 |
| 离场成交 | 2026-09-04 · 常规开盘 · @353.63 |
| 毛收益 | -6.57% |
| 成本 | +0.31% |
| 净收益 | -6.88% |
| 计入收益 | -6.88% |
| 建仓日 | 2026-09-03 · 进场不早于新闻时刻 + 2 分钟 |
做空 RARE.US Ultragenyx Pharmaceutical
| 收益状态 | -8.33% 已平仓 |
|---|---|
| 进场成交 | 2026-09-03 · 盘前首笔 · 09-03 16:01 北京 · @14.3192 |
| 离场成交 | 2026-09-04 · 常规开盘 · @15.475 |
| 毛收益 | -8.07% |
| 成本 | +0.26% |
| 净收益 | -8.33% |
| 计入收益 | -8.33% |
| 建仓日 | 2026-09-03 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-27 15:43
研究档案
结论摘要
Snowflake Q2 FY27收入$1.55B超预期4.7%、EPS超预期38%、产品收入+37% YoY加速，上调全年产品收入指引4%至$6.07B。Mizuho/Stifel/Canaccord分别上调目标至$425/$450/$450。盘前+23%至$376仍低于目标价13-20%。事件前股价连跌(-4.37%/-3.51%)无抢跑迹象，属真实surprise。Ultragenyx Phase 3 apazunersen(Angelman)失败，Canaccord目标从$83降至$37，盘前-47%。药物失败确定性高但-47%后剩余空间有限，部分分析师仍维持Buy。
关键理由
- Snowflake产品收入+37% YoY加速，AI需求驱动，上调全年指引4%至$6.07B，多家目标$425-$450仍高于盘前价13-20%
- 事件前股价连跌两日(-3.5%/-4.4%)无抢跑，属真实预期差，盘后成交量$13.9亿确认机构参与
- Ultragenyx Phase 3 Angelman药物确定性失败，多家降级，短期仍有分析师下调目标价和基金清仓卖压
主要风险
- Snowflake盘前已+23%突破52周高点，开盘后可能冲高回落/获利了结；若开盘价>$383(盘前高点)则追高风险极大
- Ultragenyx -47%后Canaccord仍维持Buy/$37目标(当前$14)，存在超跌反弹风险，做空剩余空间有限
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-09-03 · 影响 none
Stifel指出股价六个月已涨84%，当前市值$106B；但分析师目标$425-$450仍高于盘前价，未找到有效反证
检索:Snowflake SNOW overvalued risk sell the news gap fade 原文 ↗ - 做空前查反向 · 来源 kb_search · 日期 2026-09-03 · 影响 weakens
Canaccord维持Buy/$37目标(当前$14)，暗示可能超跌；6月文章称公司正转型为focused rare disease platform，有4个已批准产品
检索:Ultragenyx RARE oversold bounce buy the dip after drug failure 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足，依赖基本面和分析师目标价判断；降低confidence至6，仓位降至small
方向:无高相似先例可用；基于基本面分析判断方向
涨幅量级:无法用先例校准幅度；参考分析师目标价$425-$450作为上行参考
形态:无先例数据判断是否见光死
工具执行结果 · 成功 11 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 583 ms
{"result": "search_processed_events:agent query=`broadcom avgo earnings forecast underwhelming ai chip | campbell's cpb dividend cut guidance | hewlett packard enterprise hpe earnings sales miss | netapp ntap raised forecast stoc`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、7388 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 - kb_search 成功 stock_tools HTTP · 3,002 ms
{ - kb_search 成功 stock_tools HTTP · 2,207 ms
{ - kb_search 成功 stock_tools HTTP · 2,018 ms
{ - stock_quote 成功 stock_tools HTTP · 251 ms
{ - stock_quote 成功 stock_tools HTTP · 899 ms
{ - stock_quote 成功 stock_tools HTTP · 547 ms
{ - search_case_library 成功 stock_tools HTTP · 37 ms
{"result": "search_case_library「SNOW.US」无历史决策命中(我们过去没在这些标的上决策过,或历史尚未回填)。\n◆ SNOW.US：相关历史决策 69 条 · 其中该标的 ENTER 7 条(10.1%) · 已结算 1 笔 · 胜率 0% · 中位 -1.47% · 均值 -1.47% ⚠️只有 1 笔,样本太薄,只能当线索不能当规律\n↑ 胜率/收益口径:ENTER 当日之后 T+1 开盘入场、次日开盘出场,做空腿已按方向取反(所以正数=这个方向做对了)。统计的只有★那只票自己的腿。"} - search_case_library 成功 stock_tools HTTP · 14 ms
{"result": "search_case_library「RARE.US」无历史决策命中(我们过去没在这些标的上决策过,或历史尚未回填)。\n◆ RARE.US：相关历史决策 29 条 · 其中该标的 ENTER 5 条(17.2%) · 尚无已结算收益(都还没到出场)"} - kb_search 成功 stock_tools HTTP · 1,244 ms
{ - kb_search 成功 stock_tools HTTP · 1,079 ms
{
原文全文
展开原文 · 2,413 字
S&P 500 Index futures are little changed as of 7:53 a.m. in New York. Technology shares are in focus, following results from with chipmaker Broadcom and Hewlett Packard Enterprise.
Nasdaq 100 futures are down 0.3% Dow Jones Industrial Average futures are up 0.2% The MSCI World Index is up 0.2%
Here are some of the biggest US movers before the bell:
Magnificent Seven: Social media giant Meta (META) released its most powerful artificial intelligence model yet. Shares are up about 0.7%.Tesla (TSLA) +1.2%, Alphabet (GOOGL) +0.3%, Amazon (AMZN) +0.2%, Microsoft (MSFT) +0.5%, Nvidia (NVDA) -0.4%, Apple (AAPL) -0.2% Advasa (ADBT) falls 11% after the Japan-based financial technology company, which is listed in the US, said CFO Katharyn Field had resigned. Argan (AGX) rises 6% after the construction company reported revenue for the second quarter that beat the average analyst estimate. Broadcom (AVGO) falls 3% after the chipmaker’s results and forecast were seen as underwhelming. The company predicted a boom in artificial intelligence chip sales over the next two years. Campbell’s (CPB) falls 5% after the food company cut its dividend and provided disappointing guidance. Ciena (CIEN) rises 1% after the maker of equipment used by telecom companies posted third quarter results. Envista (NVST) climbs 2% after JPMorgan upgraded the dental company to overweight, saying the firm is entering its investor day event later this month from a position of improved execution. Hewlett Packard Enterprise (HPE) falls 4% after reporting increasing sales that didn’t meet high expectations from investors. NetApp (NTAP) is down 8%, even after the data storage and management company raised its full-year forecast. The stock has been a strong performer this year, up nearly 70% as of its last close. Snowflake (SNOW) jumps 24% after the software company’s second-quarter results beat expectations and the company raised its full-year forecast for product revenue. Analysts note another quarter of product revenue acceleration driven by AI demand. Ultragenyx Pharmaceutical (RARE) plunges 44% after the biotech’s experimental drug aimed at treating a rare genetic disorder failed to meet its primary endpoint in a study. The disappointment prompted several brokerages to downgrade their ratings on the stock. Victoria’s Secret (VSXY) falls 18% after the company boosted guidance but showed a slower pace of growth.
Nasdaq 100 futures are down 0.3% Dow Jones Industrial Average futures are up 0.2% The MSCI World Index is up 0.2%
Here are some of the biggest US movers before the bell:
Magnificent Seven: Social media giant Meta (META) released its most powerful artificial intelligence model yet. Shares are up about 0.7%.Tesla (TSLA) +1.2%, Alphabet (GOOGL) +0.3%, Amazon (AMZN) +0.2%, Microsoft (MSFT) +0.5%, Nvidia (NVDA) -0.4%, Apple (AAPL) -0.2% Advasa (ADBT) falls 11% after the Japan-based financial technology company, which is listed in the US, said CFO Katharyn Field had resigned. Argan (AGX) rises 6% after the construction company reported revenue for the second quarter that beat the average analyst estimate. Broadcom (AVGO) falls 3% after the chipmaker’s results and forecast were seen as underwhelming. The company predicted a boom in artificial intelligence chip sales over the next two years. Campbell’s (CPB) falls 5% after the food company cut its dividend and provided disappointing guidance. Ciena (CIEN) rises 1% after the maker of equipment used by telecom companies posted third quarter results. Envista (NVST) climbs 2% after JPMorgan upgraded the dental company to overweight, saying the firm is entering its investor day event later this month from a position of improved execution. Hewlett Packard Enterprise (HPE) falls 4% after reporting increasing sales that didn’t meet high expectations from investors. NetApp (NTAP) is down 8%, even after the data storage and management company raised its full-year forecast. The stock has been a strong performer this year, up nearly 70% as of its last close. Snowflake (SNOW) jumps 24% after the software company’s second-quarter results beat expectations and the company raised its full-year forecast for product revenue. Analysts note another quarter of product revenue acceleration driven by AI demand. Ultragenyx Pharmaceutical (RARE) plunges 44% after the biotech’s experimental drug aimed at treating a rare genetic disorder failed to meet its primary endpoint in a study. The disappointment prompted several brokerages to downgrade their ratings on the stock. Victoria’s Secret (VSXY) falls 18% after the company boosted guidance but showed a slower pace of growth.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。